Targeted drug conjugates: principles and progress

被引:208
作者
Garnett, MC [1 ]
机构
[1] Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England
关键词
monoclonal antibodies; immunoglobulins; immunoconjugates; anti-cancer drugs; anthracyclines; vinca alkaloids; anti-folates; enediynes; macrolide antibiotics;
D O I
10.1016/S0169-409X(01)00227-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Reports of targeting drugs using antibodies have appeared in the literature since 1958, but exciting clinical results in this field have only been reported in the last few years. Progress in this field has occurred largely through an understanding how drug-immunoconjugates work. The objective of this review is to draw together the fundamental principles on which this field of work is based, to examine the evidence supporting those principles, and the effectiveness and selectivity of targeted drug conjugates. The activity of many drug-immunoconjugates can now largely be accounted for by the underlying principles. Excellent development work, both with conventional anti-cancer agents and very potent drugs have led to a number of interesting clinical trials. In the best Phase I and II trials, good evidence of effectiveness have been reported, which suggest that drug-immunoconjugates may now be heralding a new era for chemotherapy. (C) 2001 Elsevier Science BY All rights reserved.
引用
收藏
页码:171 / 216
页数:46
相关论文
共 226 条
  • [41] Synthesis and antitumor activity of the immunoconjugate BR96-Dox
    Firestone, RA
    Willner, D
    Hofstead, SJ
    King, HD
    Kaneko, T
    Braslawsky, GR
    Greenfield, RS
    Trail, PA
    Lasch, SJ
    Henderson, AJ
    Casazza, AM
    Hellstrom, I
    [J]. JOURNAL OF CONTROLLED RELEASE, 1996, 39 (2-3) : 251 - 259
  • [42] FITZPATRICK JJ, 1995, ANTI-CANCER DRUG DES, V10, P1
  • [43] FITZPATRICK JJ, 1995, ANTI-CANCER DRUG DES, V10, P11
  • [44] PREPARATION OF 4 DAUNOMYCIN-MONOCLONAL ANTIBODY 791T/36 CONJUGATES WITH ANTI-TUMOR ACTIVITY
    GALLEGO, J
    PRICE, MR
    BALDWIN, RW
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1984, 33 (06) : 737 - 744
  • [45] GARNETT MC, 1986, EUR J CELL BIOL, V41, P214
  • [46] GARNETT MC, 1986, CANCER RES, V46, P2407
  • [47] GARNETT MC, 1988, BRIT J CANCER, V58, P251
  • [48] GARNETT MC, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P139
  • [49] PREPARATION AND PROPERTIES OF A DRUG-CARRIER-ANTIBODY CONJUGATE SHOWING SELECTIVE ANTIBODY-DIRECTED CYTO-TOXICITY INVITRO
    GARNETT, MC
    EMBLETON, MJ
    JACOBS, E
    BALDWIN, RW
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1983, 31 (05) : 661 - 670
  • [50] GARNETT MC, 1985, ANTI-CANCER DRUG DES, V1, P3